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A comparison between health research
output and burden of disease in Arab
countries: evidence from Palestine
Loai Albarqouni1* , Khamis Elessi2 and Niveen M. E. Abu-Rmeileh3
Abstract
Background: Research conducted on conditions responsible for the greatest disease burden should be given the
highest priority, particularly in resource-limited settings. The present study aimed to assess the research output in
relation to disease burden in Palestine and to identify the conditions which are under- or over-investigated, if any.
Methods: We searched PubMed and Scopus for reports of original research relevant to human health or healthcare
authored by researchers affiliated with Palestinian institutions and published between January 2000 and December
2015. We categorised the condition studied in included articles using the Global Burden of Disease (GBD) taxonomy.
Data regarding burden of disease (percentage of deaths and disability-adjusted life years (DALYs)) was obtained from
the Palestine profile in the GBD study. We examined the degree of discordance between the observed number of
published articles for each disease/condition with the expected number based on the proportion of disease burden
of that disease/condition.
Results: Our search identified 2469 potentially relevant records, from which 1650 were excluded following the
screening of titles and abstracts. Of the remaining 819 full-text articles, we included 511 in our review. Communicable
(infectious) diseases (n = 103; 20%) was the condition with the highest number of published studies. However, cancer
(n = 15; 3%) and chronic respiratory diseases (n = 15; 3%) were the conditions with the lowest number of published
studies. Research output was poorly associated with disease burden, irrespective of whether it was measured in terms
of DALYs (rho = −0.116, P = 0.7) or death (rho = 0.217, P = 0.5). Cardiovascular disease, cancer, and maternal and
neonatal deaths accounted for more than two-thirds of the total deaths in Palestine (67%), but were infrequently
addressed (23%) in published articles.
Conclusions: There is evidence of research waste measured by a mismatch between the health burden of certain
diseases/conditions and the number of published research reports on those diseases/conditions in Palestine. A national
research priority-setting agenda should be developed to meet the local community’s need for quality evidence
to implement independent and informed health policies.
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Background
Palestine, a Middle East and North Africa (MENA)
region country, consists of the West Bank, including
East Jerusalem, and the Gaza Strip [1]. It has a population
of 4.8 million, 42% of whom are registered refugees – in-
deed, 26% and 68% of those living in the West Bank
and Gaza, respectively, are refugees [2]. Over the past
decades, Palestinians have undergone a rapid epidemio-
logical transition characterised by a growing burden of
non-communicable diseases (NCDs) such as cardiovascu-
lar disease (CVD), diabetes and cancer [3].
Palestine, as elsewhere, is facing scarce financial
resources and limited research infrastructure, imped-
ing the allocation of adequate resources to health
research development [4]. Thus, it is of paramount
importance to maximise the utilisation of the, albeit
inadequate, resources allocated to health research by
prioritising the necessary evidence required by the
Palestinian community to develop independent and
informed health policies.
Substantial gaps exist between the health research that
is needed and that which is conducted, indicating a lack
of appropriate prioritisation of health research [5]. In
their 2009 Lancet seminal report ‘Avoidable waste in the
production and reporting of research evidence’ [6],
Chalmers and Glasziou noted that the dramatic mismatch
between questions addressed by researchers and questions
of relevance to the community is one of the factors
contributing to the estimated 85% waste in health and
medical research. Research prioritisation is therefore
required to guide resource allocation to areas of highest
priority and to strengthen the links between research,
policy and action [7]. There is a need for an account-
able, transparent and sustainable approach for research
prioritisation on the basis of societal needs (e.g. disease
burden) [8]. The burden of disease is a measure that
represents the relative impact of different diseases and
conditions on population health, and is frequently
measured by two indices – mortality (i.e. total deaths)
and morbidity (i.e. disability-adjusted life years (DALYs)).
The highest priority should be given to research
conducted on conditions that most substantially con-
tribute to disease burden. Topic coverage in research
output may serve as a proxy of research prioritisation,
with imbalances between the burden of disease and
the research output likely indicating specific diseases/
conditions that are relatively under- or over-
investigated compared to their attributable burden.
Highlighting this imbalance is therefore critical in
providing guidance to stakeholders/policy-makers on
the allocation of limited resources in health research.
A recent analysis showed a weak association between
the global burden of disease and the number of pub-
lished randomised trials [9]. However, there are no
previous studies examining the association between
burden of disease and research output in Palestine or
in the MENA region. This information can inform
policy-makers on the gaps between health research
needs and research conducted in Palestine, with impli-
cations on research prioritisation, funding allocations
and research agenda-setting in Palestine. In this study,
we compared the distribution of the output of pub-
lished health and medical research from Palestine and
the distribution of the burden of disease in Palestine
and investigated whether specific conditions/diseases
are under- or over-investigated.
Methods
We used the same dataset as in a previous analysis that
aimed to assess the quality of reporting of Palestinian
medical and health research, but we updated the search
till the end of 2015 [10].
Data sources and search strategy
We searched PubMed and Scopus databases for articles
of Palestinian medical and public health studies
published between January 1, 2000, and December 31,
2015. We searched for the following terms in the author
affiliation, title or abstract: ‘palestin*’, ‘jerusalem’, ‘west bank’,
‘gaza’, ‘oPt’, or ‘occupied Palestinian territories’. No
language restrictions were applied.
Eligibility criteria
We included all articles of original research authored
and/or co-authored by researchers affiliated with
Palestinian institutions. We included only articles
that reported medical and health studies. We included
quantitative studies, whether observational (cross-sec-
tional, cohort, case–control studies, and case series and
reports), interventional (controlled trials) or systematic
reviews and meta-analyses. We excluded studies where
none of the authors was affiliated with a Palestinian in-
stitution, even if they included Palestinian participants.
We also excluded studies not involving humans as well
as studies on health systems research.
Study selection
Two reviewers independently screened the titles and
abstracts of retrieved records against our eligibility
criteria. The same two reviewers independently
assessed the full texts of all potentially eligible articles.
Disagreements between reviewers were resolved by
discussion and consensus. Reasons for exclusion were
identified and documented.
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Data collection
Two reviewers independently and in duplicate used a
data extraction form to extract the required data from
each article, including (1) bibliographic details – authors,
journal name, and year of publication; (2) number of
authors, the first author’s affiliation and any national,
regional (i.e. MENA region) or international collaboration;
(3) description of disease or condition evaluated according
to groups of global burden of disease [11] (in studies
tackling more than one disease, we considered the
disease relevant to the primary objective of the study,
if not reported, then the most highlighted disease
throughout the article); (4) sample size (in case of a
systematic review and/or meta-analysis, we considered
the number of included studies as the sample size);
(5) type of study question (prevalence, etiological,
diagnostic, prognostic, interventional) and study design
(systematic review, randomised controlled trials (RCT),
non-randomised intervention study (e.g. controlled trials),
cohort, case–control, cross-sectional and case report/
series) [12]; and (6) source of funding (international, local
government, academic institution or industry, and not re-
ported/unclear).
Burden of disease
Data on the burden of disease in Palestine were obtained
from the Global Burden of Disease (GBD) 2015 study
[13]. GBD is a systematic evaluation and quantification
of the burden of major diseases and conditions cate-
gorised by age, sex and country. Burden is estimated
using both deaths and DALYs [11]. We obtained
country-specific estimates of the total number of DALYs
and deaths in Palestine for each disease/condition, with
death defined as the number of deaths due to a specific
cause (disease or injury) within the total population.
DALYs is a standardised metric that reflects the discrep-
ancy between existing and ideal health status. DALYs ac-
count for both years of life lost due to premature death
and years lived with disability.
Data analyses and interpretation
Descriptive analysis was performed using frequency
and percentages. We plotted the total number of
research articles for each disease/condition category
against their associated deaths (number of deaths per
100,000 population) and DALYs (number of DALYs per
100,000 population). We assessed the correlation between
research output and burden of disease using the Spearman
correlation test (i.e. Spearman’s rho coefficient). We also
assessed whether the distribution of research output has
matched the distribution of disease burden (i.e. in terms
of both deaths and DALYs) for each disease/condition,
by examining the degree of discordance between the
observed number of published articles for each disease/
condition with the expected/proportionate number of
published articles based on the proportion of disease
burden for that disease/condition (e.g. the expected
number of published articles for CVD = % of burden
caused by CVD × total published reports = 39.3% × 511 =
201). The difference between observed and expected
number of published articles is expected to be zero
when there is a good alignment between research out-
put and disease burden. A positive difference indicates
that the disease/condition was over-studied (i.e.
research surplus), while a negative difference suggests
that the disease/condition was under-studied (i.e.
research deficit). We used Microsoft Excel and R
software (version 3.2.3) for data preparation and analysis.
Results
Our search identified 2469 potentially relevant records,
from which 1650 were excluded based on screening
titles and abstracts. Of the remaining 819 full-text
articles, we included 511 in our review. The reasons for
excluding the 308 articles were (1) none of the authors/
co-authors was affiliated to a Palestinian institution
(36%); (2) it was an article of qualitative research (34%);
(3) it had not been conducted on individual humans (e.g.
basic science research) (16%); and (4) full texts could not
be retrieved (14%) (Fig. 1).
Characteristics of included studies
First authors of 361 (71%) articles were affiliated with
Palestinian institutions, 35 (7%) with regional institutions,
and 115 (23%) with international institutions. Of the 511
included articles, 152 (30%) involved collaboration
between more than one Palestinian institution, 31 (6%)
Fig. 1 PRISMA Flowchart of the study selection process
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between Palestinian and regional institutions, and
240 (47%) between Palestinian and international
institutions. Most (371; 73%) of the articles were co-
authored by 2–6 authors.
The number of published Palestinian medical and
health research articles increased over time, almost
doubling every 5 years (13% between 2000 and 2004,
32% between 2005 and 2010, and 55% between 2011
and 2015).
Table 1 provides information on the general characteristics
of the included articles. The most frequent study design was
cross-sectional studies (n = 381; 75%), while 16 (3%)
were controlled trials, and only 4 (0.8%) were system-
atic reviews. Most of the articles (368; 72%) presented
prevalence/association studies, 61 (12%) therapeutic
studies, 27 (5%) aetiological studies, 17 (3%) prognostic
studies, and 11 (2%) diagnostic studies. The majority of
included articles had a sample size of less than 200
participants (n = 406; 80%). Sources of funding were
not mentioned in approximately two-thirds (351;
68.7%) of the articles. Of those reporting, over two-
thirds were international (110; 21.5%).
The distribution of research output and disease burden
by disease/condition categories
The distribution of Palestinian health research output
and disease burden (DALYs and deaths) across various
diseases/conditions is presented in Table 2. Communicable
(infectious) diseases (n = 103; 20%), nutritional diseases
(n = 55; 11%), and mental and substance use disorders
(n = 54; 11%) were the conditions with the highest
number of published studies. However, cancer (n = 15;
3%), chronic respiratory (n = 15; 3%), and gastrointestinal
diseases (n = 16; 3%) were the conditions with the lowest
number of published studies.
Maternal, neonatal and congenital conditions were the
main cause of DALYs accounting for 26% of the total
DALYs in Palestine in 2015, followed by cardiovascular
(15%), musculoskeletal and neurological conditions
(11%). CVD, maternal, neonatal and congenital conditions,
and cancer were the main causes of death accounting for
39%, 15%, and 13% of the total deaths in Palestine in 2015.
Association between research output and disease burden
Cancer, CVD, and maternal, neonatal and congenital
conditions were all understudied since they have the
highest ratios of disease burden to research output
(DALYs per 100,000 population per study: 94.7, 61.9
and 111.6, respectively; deaths 100,000 population per
study: 2.7, 2.4 and 1, respectively). However, nutritional,
infectious, and mental and substance use disorders
were all over-studied with regards to their contribution
to the disease burden (DALYs 100,000 population per
study: 9.7, 11.4 and 40.1, respectively; deaths 100,000
population per study: 0, 0.2 and 0, respectively) (Table 2).
Figure 2 shows that research output was poorly correlated
with disease burden, irrespective of whether measured in
Table 1 Characteristics of included studies (n = 511)
No. of studies (%)
Total 511 (100)
Affiliation(s) of the first author
Palestine 361 (70.6)
Regional 35 (6.9)
International 115 (22.5)
Collaborations
The same Palestinian institution 88 (17.2)
Different Palestinians Institutions 152 (29.7)
Palestinian and Regional Institutions 31 (6.1)
Palestinian and International institutions 240 (47.0)
Number of authors per article
1 53 (10.4)
2–6 371 (72.6)
> 7 87 (17.1)
Publication year
2000–2004 68 (13.3)
2005–2010 164 (32.1)
2011–2015 265 (54.6)
Sample size (No. of participants)
< 50 187 (36.6)
50–200 219 (42.9)
> 200 105 (20.5)
Type of the study question
Prevalence/association 368 (72.0)
Aetiology/risk factors 27 (5.3)
Diagnosis 11 (2.2)
Therapeutic/intervention 61 (11.9)
Prognosis 17 (3.3)
Others (case report) 27 (5.3)
Study design
Cross-sectional 381 (74.6)
Systematic review 4 (0.8)
Randomised controlled studies 8 (1.6)
Non-randomised interventional studies 8 (1.6)
Cohort 38 (7.4)
Case–control 45 (8.8)
Case reports/series 27 (5.3)
Funding sources
Not reported/unclear 351 (68.7)
Local (governmental/industry/institutional) 50 (9.8)
International 110 (21.5)
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terms of DALYs (rho = −0.116, P = 0.7) or death (rho =
0.217, P = 0.5).
Expected versus observed research output
To further assess the association/proportionality between
research output and disease burden, we examined the
actual observed and expected number of studies as a
function of the disease burden (Fig. 3). The difference
between the actual and expected number of articles
demonstrates whether each condition/disease was under- or
over-represented in published Palestinian research articles
(0: matched/balanced, negative: understudies/represented:
Table 2 The distribution of research output and disease burden (DALY and death) per disease category
Disease/Condition Research output
(% total)
Rank Number
of involved
participants
Rank DALY rate
per 100,000
population
(% total DALY)a,b
Rank Death rate
per 100,000
population
(% total death)a,c
Rank DALY per
100,000
population
per studya,d
Death per
100,000
population
per studya,e
Infectious 103 (20) 1 18,101 1 1170 (5) 7 18 (6) 6 11.4 0.2
Nutritional 55 (11) 2 15,450 2 536 (3) 11 0.1 (0) 12 9.7 0
Mental 54 (11) 3 13,009 3 2163 (10) 5 1.2 (0) 11 40.1 0
Cardiovascular 52 (10) 4 9598 5 3221 (15) 2 124 (39) 1 61.9 2.4
Maternal, neonatal
and congenital
50 (10) 5 6763 6 5578 (26) 1 48 (15) 2 111.6 1
Blood, urogenital and
endocrine diseases
48 (9) 6 6629 7 1004 (5) 8 19 (6) 5 20.9 0.4
Musculoskeletal and
neurological
37 (7) 7 1744 10 2449 (11) 3 12 (4) 7 66.2 0.3
Diabetes 36 (7) 8 11,157 4 559 (3) 9 9 (3) 9 15.5 0.2
Injuries 30 (6) 9 5779 8 2314 (11) 4 28 (9) 4 77.1 0.9
Gastrointestinal 16 (3) 10 1454 11 350 (2) 12 8 (3) 10 21.9 0.5
Cancer 15 (3) 11 864 12 1420 (7) 6 40 (13) 3 94.7 2.7
Chronic respiratory 15 (3) 12 2559 9 541 (3) 10 9 (3) 8 36.1 0.6
aData on DALYs and death in Palestine were obtained from the Global Burden of Disease (GBD) 2015 study [13]
b% total DALY = (DALY rate per 100,000 population for a specific disease or condition ÷ DALY rate per 100,000 population) × 100; larger value denotes higher
contribution of this disease/condition to the total DALY in Palestine
c% total death = (death rate per 100,000 population for a specific disease or condition ÷ death rate per 100,000 population) × 100; larger value denotes higher contribution
of this disease/condition to the total deaths in Palestine
dDALYs per 100,000 population per study = (DALY per 100,000 population for a specific disease or condition ÷ research output for the same disease or condition) × 100
eDeaths per 100,000 population per study = (death per 100,000 population for a specific disease or condition ÷ research output for the same disease or condition) × 100
a b
Fig. 2 Relationship between research output (i.e. number of Palestinian medical and health research articles research published between 2000 and 15)
and burden of disease as the number of deaths up to 2015 (a) or number of disease-adjusted life years (DALYs) up to 2015 (b)
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positive: over-studied/represented). Cancer, musculoskeletal
diseases, CVD and diabetes were the most understudied
conditions relative to their burden, while infectious and
nutritional conditions were the most over-studied (Fig. 3).
Discussions
Our study indicates that there is an evident mismatch
between the distribution of disease burden and condi-
tions/diseases that were investigated in published articles
from Palestine between 2000 and 2015. It is worrisome
that CVD, maternal and neonatal diseases, and cancer
account for more than two-thirds of the total deaths in
Palestine (67%), but are infrequently addressed (23%) in
published articles.
Our findings are in line with a previous investigation
of research output (i.e. 66 RCTs published in five leading
medical journals) in Latin America that found a poor
correlation between disease burden and research output
[14]. This was also evident in a recent cross-sectional
analysis of 1097 RCTs [9], which found that global
burden of disease is poorly associated with the number of
published randomised trials (Spearman’s r = 0.35; P < 0.001)
as well as with the number of recruited participants
(Spearman’s r = 0.33; P < 0.001). Similarly, an analysis
of a random sample of 2381 records of trials registered in
the WHO’s International Clinical Trials Registry Platform
(ICTRP), found that there is little correlation between
disease burden and the global distribution of registered
clinical trials, with research and development not
adequately meeting the needs of populations in lower-
income countries [15]. A 2002 study of 1179 published
randomised trials from sub-Saharan Africa (48% from
South Africa) showed a good correlation between the
estimated burden of disease and the number of trials
performed (Spearman’s r = 0.53, P = 0.024) and the
number of participants randomised (Spearman’s r = 0.68,
P = 0.002) [16]. However, a recent sub-set analysis of all
these RCTs found that a very poor correlation between
disease burden and the number of trials (Spearman’s
r = 0.17) [9]. This can be explained by the rapid epide-
miological transition in sub-Saharan Africa, involving an
increase in NCD burden, and yet a prioritisation of com-
municable diseases (e.g. HIV and malaria) in sub-Saharan
countries’ health research systems and capacity [17, 18].
A recent scoping review of 3776 NCD-related reports
published between 2000 and 2013 from seven Arab
countries [19], found a mismatch between cause-specific
death rates and research output, with a relative surplus
of reports on cancer and a relative deficit of those on
CVDs. The subset analysis of reports from Palestine
showed a deficit of studies on both CVDs and cancer.
Fig. 3 Difference between the actual observed number of published Palestinian health research articles for each disease/condition and expected
number in proportion to disease burden
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However, this study is limited to publications related to
NCDs, to the exclusion of other diseases/conditions.
Previous investigations have also shown that there is a
mismatch between disease burden and allocated funds.
An analysis of the relation between WHO’s budgetary
allocations and burden of disease found a misalignment
between fund allocation and disease burden, with a
noticeable skew towards infectious diseases [20]. However,
Gross et al. [21] compared the estimates of National
Institute of Health disease-specific funding in 1996
with the burden of disease, and found that funding was
more strongly associated with DALYs (r = 0.62, P < 0.001)
than the number of deaths (r = 0.40, P = 0.03).
Important to note is the slight discrepancies between
the findings related to comparing research output to
death rates and DALYs, respectively. While high case
fatality rates for some conditions may inflate death rates
(e.g. CVD and cancer), disabling conditions with no
cure and long duration (e.g. musculoskeletal and
neurological) inflate DALYs. For instance, we found
that ‘Musculoskeletal and Neurological’ and ‘Injuries’
conditions were understudied when considering DALYs
but less so when considering death rates.
The observed discordance between the focus of the
published research from Palestine and disease burden
can be explained by several factors, including (1) researchers’
interest and expertise; (2) limited research infrastructure and
funding resources, which drive researchers to accept
the funder agenda, not commonly aligned with local
community needs [22–24]; and (3) lack of communication
between policy-makers and researchers to agree on
national research priorities [20, 25].
A limitation to this review is that we only searched
two databases (PubMed and Scopus) and we may have
therefore missed a number of relevant studies not
indexed therein, as well as any unpublished studies.
Similarly, excluding lab-based studies may have influenced
the results of our study (e.g. cancer studies are frequently
lab-based, and therefore more likely missed due to our
eligibility criteria). Further, there is some degree of
subjectivity in assigning each study to a particular disease
or condition. However, two reviewers assigned studies to
each category independently and in duplicate. Important
to note is that published research output may not neces-
sarily accurately reflect all work being conducted in a
particular condition/disease area. Indeed, research output
is only one of five core indicators of potential societal
benefits of health research, as described by Hanney et al.
[26] in their Payback model (i.e. a framework of five core
indicators: knowledge production, research targeting and
capacity, informing policy, health and health sector
benefits, and economic benefits). We also found that the
clear majority (96%) of health research from Palestine
were observational studies, which have limited potential
to inform health policy-making compared to a higher level
of evidence (e.g. systematic reviews and RCTs).
Implications of our findings
Establish a national medical and health research
priority-setting in Palestine
Priority-setting is essential for efficient use of limited
resources, and an integral step needed in the national
research management process to assist the allocation of
limited resources to meet national health goals. Other-
wise, there is a risk that research topics are determined
and imposed by funding organisations for their own
agenda and policies.
National research priority-setting should be derived
using transparent methodologies, including an evidence-
based systematic assessment and situation analysis.
Stakeholder involvement in the priority-setting exercise
should be inclusive to ensure the extensive participation
of researchers, clinicians, university research boards,
government, funders, civil organisations, industry, pa-
tients and the public. Crowe et al. [27] found a persistent
mismatch between patients’, clinicians’ and the research
communities’ priorities. In a recent comprehensive
assessment of health research priority-setting initiatives
in developing countries, McGregor et al. [25] found that
the majority of the 91 identified priority-setting initia-
tives took place at the global level (i.e. those with global
health agenda such as eradicating specific diseases) with
a developing country focus. However, most did not have
any evidence of implementation or follow-up.
Enhance the capacity of national researchers and urge
them to conduct prioritised research
Lack of sufficient health research capacity is still a major
barrier to conduct evidence-based health research to
inform policy and improve health [28]. The World
Health Report 2013 focused on the importance of all
nations being producers and consumers of research (i.e.
to develop a capacity to not just adopt the evidence, but
to adapt it to local circumstances [29]). Therefore,
research capacity-building should be given a higher
priority and needs to be equally valued as research out-
puts by development parties [30, 31].
Foster dialogue between researchers, policy-makers,
funders and end-users/patients
Communication between researchers, academics, decision-
makers and patients/public should be started as early as
possible during the research priority-setting and continued
throughout the research conduction. Further, results
dissemination should be fostered by knowledge transla-
tion interventions to enhance the uptake of evidence
into practice. This exchange of ideas and information
will facilitate the bridging of the gap between research
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conducted at research institutions and the community’s
and decision-makers’ needs.
Conclusions
Despite the encouraging increase in the research output
from Palestine over the last decades, there remains a
weak association between research output and burden of
disease. NCDs (e.g. CVD and cancer) receive much less
attention by researchers despite accounting for most of
the disease burden in Palestine. National research priority-
setting should be developed to meet the Palestinian
community’s need for quality evidence to establish
independent and informed health policies.
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